4 ms·
> Also, no one pressed them to sell it at cost, Oxford literally said they'd only partner with manufacturers who'd sell at cost. > they could have sold for pr
by michaelt 6y ago
> Also, no one pressed them to sell it at cost,
Oxford literally said they'd only partner with manufacturers who'd sell at cost.
> they could have sold for profit and pay/raise funding for production expansion
The EU negotiated the price for OAZ down to $2.15 a dose while the US pays $4 a dose for the same vaccine according to [1]
Let's not pretend the EU was throwing cash around, trying to fund expanded production, because they weren't.
[1] https://www.bmj.com/content/372/bmj.n281 https://www.bmj.com/content/372/bmj.n281
- libertine 6y agoWho pressed them to accept both the Oxford conditions, or the EU conditions? The EU wasn't throwing cash around, they just upfronted €336 million out of €750 million[1]. [1]https://www.fiercepharma.com/manufacturing/az-nets-396m-downpayment-for-300m-plus-eu-vaccine-doses https://www.fiercepharma.com/manufacturing/az-nets-396m-down... >Let's not pretend the EU was throwing cash around, trying to fund expanded production, because they weren't. I really don't get this argument, in case you didn't notice, the production capacity of the EU was already there, it was the UK and USA that had to catch up to it. It's not by random chance that the first vaccines came from EU, it's years of investments there. Now you might say, it's yet not enough - well you're right, specially if half of that production capacity is being exported.